NEW YORK / Dec 02, 2025 / Business Wire / Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that it is well along in the multi-step and time-consuming process that is required to call a Special Meeting of Shareholders (the “Special Meeting”) at STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA) to remove three directors from the Company’s Board of Directors (the “Board”). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose the current agreement to sell the Company to Alcon Inc. (“Alcon”) (NYSE: ALC), and believes changes to STAAR’s Board are needed to restore investor confidence in the Board’s decision making and the sale process.
At the Special Meeting, Broadwood intends to seek the removal of the three incumbent directors it believes are most responsible for incentivizing, facilitating, and promoting the sale of the Company to Alcon at the wrong time, after a flawed process, and at an inadequate price:
Neal C. Bradsher, Founder and President of Broadwood, said:
“By agreeing to — and recklessly persisting with — a deeply flawed transaction that has drawn overwhelming opposition from shareholders and all three major proxy advisory firms, the Board has, in our view, demonstrated its lack of fidelity to the interests of shareholders and other stakeholders.
As STAAR’s largest shareholder, we have been urging the Board for weeks to strengthen its composition by appointing new directors with the independence, expertise, and shareholder alignment necessary to steward the Company responsibly and restore investor trust. The Board should surely understand that, among other things, the credibility of this thrice-delayed vote and belatedly re-engineered sale process would benefit greatly from the oversight of new directors. We anticipate that a refreshed Board would consider, among other matters, how to run a full, fair, independent, and open strategic alternatives process to maximize value that is untainted by the process issues and conflicts of interest that afflicted this proposed transaction with Alcon.
Unfortunately, the Board ignored these calls to action, and STAAR’s future remains in the hands of the same individuals who designed and executed a flawed sale process. Accordingly, we have been engaged in the byzantine process required by STAAR to call the Special Meeting to remove those directors who, in our view, are most responsible for orchestrating and perpetuating this misbegotten proposed transaction. Broadwood is not seeking, and has never sought, control of STAAR. Shareholders deserve a board that truly represents them.
We believe Board change is urgently needed. We urge STAAR’s Board to respect the rights of shareholders by refraining from any gamesmanship or defensive maneuvers and to hold without delay the Special Meeting for which we are calling. It is time for the Board to listen to shareholders’ voices so that STAAR can finally realize its full potential.”
Shareholders can find additional information at www.LetSTAARShine.com.
About Broadwood
Broadwood Partners, L.P. is managed by Broadwood Capital, Inc. Broadwood Capital is a private investment firm based in New York City. Neal Bradsher is the President of Broadwood Capital.
Certain Information Concerning the Participants
Special Meeting of Shareholders Originally Scheduled for October 23, 2025
Broadwood Partners, L.P., Broadwood Capital, Inc., Neal C. Bradsher, Richard T. LeBuhn, Natalie R. Capasso, Raymond A. Myers and Jason J. Martin (collectively, the “Participants”) are participants in the solicitation of proxies from the shareholders of the Company in connection with the special meeting of shareholders originally scheduled for October 23, 2025 and most recently postponed to be held on December 19, 2025 (including any further adjournments, postponements, reschedulings or continuations thereof, the “Proposed Merger Special Meeting”). The Participants have filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company’s shareholders for the Proposed Merger Special Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE PROPOSED MERGER SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company’s shareholders and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.
Special Meeting of Shareholders to Remove Members of the Board
The Participants also intend to file a definitive proxy statement and an accompanying GREEN Proxy Card with the SEC to be used to solicit proxies with respect to removing members of the Board and any other proposals that may come before a future and yet to be called or otherwise scheduled special meeting of shareholders (including any adjournments, postponements, reschedulings or continuations thereof, the “Shareholder Meeting”). The Shareholder Meeting will be separate, distinct and unrelated to the Proposed Merger Special Meeting, and the Participants believe that the Shareholder Meeting will have no effect on the outcome of the Proposed Merger Special Meeting. The Participants do not believe that there is any lawful reason that would prevent or prohibit the Participants from calling the Shareholder Meeting, regardless of the outcome of the shareholder vote at the Proposed Merger Special Meeting, and do not make any representation related to whether the Company may contest, or otherwise challenge, the Participants’ ability to call the Shareholder Meeting. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SHAREHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all of the Company’s shareholders and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.
Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on November 21, 2025 and is available here.
| Last Trade: | US$25.38 |
| Daily Change: | -1.22 -4.59 |
| Daily Volume: | 977,673 |
| Market Cap: | US$1.250B |
November 05, 2025 August 06, 2025 May 07, 2025 April 24, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load